需要指出的是，张忠此次拟减持的股份数量为不超过9.83万股，正好卡在高管每年最高可减持其所持股份25%的红线附近。《每日经济新闻》记者还注意 到，通光线缆2011年A股上市解禁以来，张忠尚未实施过任何减持，如此次减持计划实施，将是其首次减持通光线缆股份套现。 此外，Wind金融终端数据显示，通光集团上一次减持通光线缆股份还是发生在2020年，当年通光集团累计减持了342万股股份。也就是说，这次抛出减持不 超3%的计划，打破了通光集团近年来在减持操作上的较长静默期。分析认为，结合近期A股光纤及特高压板块的整体上攻行情，大股东选择在此时点时隔 多年再度抛出减持计划，似有逢高兑现之意。 | 代码 | 证券简称 | 报告期 | 期末参考市值(乙) | 持股数量(万股) | 持有限售股数量(万股) 持股数量变动 | | --- | --- | --- | --- | --- | --- | | | | 2025年中报 | 18.05 | 18.283.00 | 0 不变 | | | | :2025年一季报 | 15.91 | 18.283.00 | 0 不变 | | | | :2024年年报 | 15.03 | 18, ...

引人关注的是，东方雨虹在2023年和2024年这两年的第四季度净利润表现出大幅变脸。如2023年第一季 度至第三季度，公司分别实现净利润3.86亿元、9.49亿元、10.19亿元，分别同比增长21.53%、46.15%、 48.05%。但2023年第四季度公司净利润为亏损8016.82万元，同比下降117.18%。2024年第一季度至第三 季度，公司分别实现净利润3.48亿元、5.96亿元、3.34亿元，分别同比下降9.81%、37.23%、67.23%。而 2024年第四季度，公司净利润突然变脸为亏损11.69亿元，同比下降1358.30%。 虽然业绩承压，但东方雨虹（002271）股价近半年表现相对强势，而近期更是出现加速上涨态势。不 过，东方雨虹实控人却抛出减持计划。1月27日晚，东方雨虹发布控股股东减持计划公告。公司控股股 东、实际控制人李卫国先生计划在公告披露之日起15个交易日后的3个月内(自2026年2月26日至2026年5 月25日)，以大宗交易或集中竞价交易方式减持公司股份不超过7166.08万股(占本公司总股本比例不超过 3%)。 公司2025年第四季度的净利润有没有可能出现类似变脸的情况呢 ...

Group 1 - The core point of the article is that Changying Precision (300115) announced a stock option incentive plan for 2025, granting 14.262 million stock options to 870 eligible recipients, amidst concerns about potential arbitrage by executives who disclosed a share reduction plan shortly before participating in an employee stock ownership plan [2][3][5] - The company operates in the electronic components sector, focusing on electromagnetic shielding components, precision connectors, and parts for humanoid robots, with its stock price having doubled since early 2025 [3] - The stock reduction plan was disclosed on December 17, 2025, with five executives planning to sell a total of 132,300 shares, citing personal financial needs [4][5] Group 2 - The employee stock ownership plan allows executives to purchase shares at a significant discount, with the purchase price set at 20.56 yuan per share, compared to a market price around 40 yuan, raising questions about potential "high sell, low buy" practices [7][8] - Legal experts noted that while the actions of the executives are technically compliant with existing regulations, they may create a perception of unfairness in the market, suggesting a need for regulatory improvements to address potential arbitrage opportunities [8][10] - The current regulatory framework lacks clear restrictions on executives participating in employee stock ownership plans during share reduction windows, which could lead to exploitation of this "gray area" [10]

Group 1 - The company's stock price has increased significantly, with a cumulative rise of 80.52% since December 1, 2025, outperforming the Shanghai Composite Index, while the company's fundamentals have not changed significantly [2][3] - The company's static price-to-earnings (P/E) ratio was reported as negative on January 9, 2026, deviating from the industry average P/E ratio of 42.47 for specialized equipment manufacturing and 89.56 for the aerospace industry [4] - The stock turnover rate has increased significantly since December 30, 2025, with a cumulative turnover rate of 169.27% and an average daily turnover rate of 21.16%, indicating heightened trading activity [5] Group 2 - The company anticipates a net loss of approximately 220 million yuan for the fiscal year 2025, with a net profit of approximately -210 million yuan after excluding non-recurring gains and losses [6] - The company's main business involves specialized equipment, modified vehicles, flexible pipes, pressure vessels, and artistic engineering, with applications in various sectors such as petrochemicals, hydropower, nuclear power, and energy equipment, and no significant changes in revenue structure are expected in the short term [7]

Group 1 - On the first trading day of 2026, several companies with market capitalizations below 10 billion announced the early termination of their share reduction plans [1][2] - Hezhong China disclosed that its controlling shareholder planned to reduce its stake by up to 796.1 million shares, representing 2% of the total share capital, but decided to terminate the plan early due to meeting funding needs and expressing confidence in the company's future [1] - Hezhong China's stock price has been rising since late October, despite warnings of performance decline and losses due to macroeconomic changes and policy adjustments in the medical industry [1] Group 2 - As of January 5, Hezhong China's total market value is 9.2 billion [2] - Haisen Pharmaceutical announced that some directors and senior management completed their share reduction plans, while one executive, based on confidence in the company's future, decided to terminate their plan early [2] - The financial director of Haisen Pharmaceutical reduced 3,000 shares during the planned period, while other executives completed their reductions totaling 102,900 shares, representing 0.0675% of the total share capital [2] Group 3 - AoJing Medical disclosed that its executives decided to terminate their share reduction plans early due to market conditions and personal circumstances [3] - Executives at AoJing Medical had previously planned to reduce their stakes from December 3, 2025, to March 3, 2026, but opted to halt the plan [3] - The reductions by executives at AoJing Medical accounted for 0.07%, 0.05%, 0.04%, and 0.03% of the total share capital, respectively [3]

Core Viewpoint - The company announced an abnormal stock price fluctuation with a cumulative increase of 20.95% over three consecutive trading days, deviating from the Shanghai Composite Index by 21.47% [1] Financial Performance - For the period from January to September 2025, the company's net profit attributable to shareholders was 172.5 million yuan, representing a year-on-year decrease of 12.06% [1] Corporate Actions - The company plans to acquire assets and raise funds, pending regulatory review [1] - The general manager and board member, Zhang Chuqian, along with his concerted actions, reduced their holdings by a total of 4.0598 million shares, accounting for 1.23% of the total share capital on December 8 [1] - On December 12, the company decided to terminate the share reduction plan early, committing not to reduce holdings from December 13, 2025, to December 12, 2026 [1]

Core Viewpoint - Hengbo Co., Ltd. announced that its shareholder, Hainan Mingxu Enterprise Management Partnership (Limited Partnership), had initially planned to reduce its holdings within three months after the announcement of the reduction plan, but ultimately did not sell any shares during the designated period [1] Summary by Relevant Sections - **Shareholder Reduction Plan** - Hainan Mingxu intended to reduce its holdings by up to 3.00% of the company's total share capital, excluding repurchased shares, which amounts to a maximum of 304.4 million shares [1] - The plan included a limit of no more than 1% reduction through centralized bidding and 2% through block trading within any consecutive 90 natural days [1] - **Current Shareholding Status** - As of the expiration of the reduction plan, Hainan Mingxu did not reduce any shares and continues to hold 3.67 million shares, representing 3.62% of the total share capital [1]